AbbVie Inc (ABBV)vsStevanato Group SpA (STVN)
ABBV
AbbVie Inc
$202.78
+1.09%
HEALTHCARE · Cap: $368.38B
STVN
Stevanato Group SpA
$18.28
+0.27%
HEALTHCARE · Cap: $4.99B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 5121% more annual revenue ($62.82B vs $1.20B). STVN leads profitability with a 11.7% profit margin vs 5.8%. ABBV appears more attractively valued with a PEG of 0.56. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
STVN
Hold46
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-23.7%
Fair Value
$168.52
Current Price
$202.78
$34.26 premium
Margin of Safety
+81.1%
Fair Value
$82.46
Current Price
$18.28
$64.18 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Premium valuation, high expectations priced in
2.9% earnings growth
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.56 suggests the stock is reasonably priced for its growth.
Bull Case : STVN
The strongest argument for STVN centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 102.2x leaves little room for execution misses.
Bear Case : STVN
The primary concerns for STVN are P/E Ratio, EPS Growth, PEG Ratio.
Key Dynamics to Monitor
STVN carries more volatility with a beta of 0.76 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 46/100) and 12.4% revenue growth. STVN offers better value entry with a 81.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Stevanato Group SpA
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Stevanato Group SpA (STVN) is a prominent global leader in advanced drug delivery systems, offering innovative integrated solutions specifically designed for the pharmaceutical and biotechnology industries. The company specializes in the design and production of high-quality glass and polymer packaging for injectable medications, enhancing the efficiency and reliability of drug administration. With a dedicated focus on quality, sustainability, and technological advancement, Stevanato is strategically positioned to capitalize on the increasing demand within the biopharmaceutical sector, making it an appealing investment opportunity for institutional investors seeking exposure to healthcare innovation.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?